AU2021229654A1 - Vaccine against african swine fever virus infection - Google Patents

Vaccine against african swine fever virus infection Download PDF

Info

Publication number
AU2021229654A1
AU2021229654A1 AU2021229654A AU2021229654A AU2021229654A1 AU 2021229654 A1 AU2021229654 A1 AU 2021229654A1 AU 2021229654 A AU2021229654 A AU 2021229654A AU 2021229654 A AU2021229654 A AU 2021229654A AU 2021229654 A1 AU2021229654 A1 AU 2021229654A1
Authority
AU
Australia
Prior art keywords
ep402r
protein
seq
amino acid
asf virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021229654A
Other languages
English (en)
Inventor
Simon Davis
Linda DIXON
Shinji IKEMIZU
Yuan Jenq LUI
Anusyah RATHAKRISHNAN
Ana REIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Pirbright Institute
Kumamoto University NUC
Original Assignee
University of Oxford
Pirbright Institute
Kumamoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by University of Oxford, Pirbright Institute, Kumamoto University NUC filed Critical University of Oxford
Publication of AU2021229654A1 publication Critical patent/AU2021229654A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2021229654A 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection Pending AU2021229654A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2003292.6 2020-03-06
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GB2003289.2 2020-03-06
GB2005880.6 2020-04-22
GB2005878.0 2020-04-22
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2013541.4 2020-08-28
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050562 WO2021176236A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
AU2021229654A1 true AU2021229654A1 (en) 2022-11-03

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021229654A Pending AU2021229654A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection
AU2021231402A Pending AU2021231402A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021231402A Pending AU2021231402A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Country Status (13)

Country Link
US (3) US20240293525A1 (https=)
EP (3) EP4114454A1 (https=)
JP (2) JP2023516713A (https=)
KR (2) KR20230013016A (https=)
CN (3) CN115397463A (https=)
AU (2) AU2021229654A1 (https=)
BR (2) BR112022016893A8 (https=)
CA (2) CA3170043A1 (https=)
CL (2) CL2022002412A1 (https=)
CO (2) CO2022014152A2 (https=)
MX (2) MX2022010373A (https=)
PH (2) PH12022552084A1 (https=)
WO (3) WO2021176235A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN120282794A (zh) * 2022-08-04 2025-07-08 T·马尔科姆 针对非洲猪瘟病毒的猪的预防和感染后治疗的显性负性抗原方法
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
BR112022016893A2 (pt) 2023-01-24
CA3170058A1 (en) 2021-09-10
CN116133680A (zh) 2023-05-16
BR112022016893A8 (pt) 2023-02-28
US20240293525A1 (en) 2024-09-05
EP4114453A1 (en) 2023-01-11
WO2021176235A1 (en) 2021-09-10
CN115397463A (zh) 2022-11-25
CO2022014256A2 (es) 2022-12-30
EP4114454A1 (en) 2023-01-11
EP4114455A1 (en) 2023-01-11
WO2021176236A1 (en) 2021-09-10
US20230124042A1 (en) 2023-04-20
MX2022010372A (es) 2023-01-19
KR20230013017A (ko) 2023-01-26
JP2023516713A (ja) 2023-04-20
CN115605223A (zh) 2023-01-13
KR20230013016A (ko) 2023-01-26
CA3170043A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
PH12022552084A1 (en) 2024-02-26
CL2022002412A1 (es) 2023-03-03
JP2023516709A (ja) 2023-04-20
CL2022002416A1 (es) 2023-03-03
MX2022010373A (es) 2023-01-19
PH12022552086A1 (en) 2023-11-20
CO2022014152A2 (es) 2023-02-16
AU2021231402A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
AU2021229654A1 (en) Vaccine against african swine fever virus infection
Moormann et al. Molecular cloning and nucleotide sequence of hog cholera virus strain Brescia and mapping of the genomic region encoding envelope protein E1
MXPA01012723A (es) Vacuna de virus recombinante de viruela contra circovirus porcino.
CN102459578A (zh) 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法
JP7587612B2 (ja) 改変ｐｅｄｖスパイクタンパク質
CN118973610A (zh) 通过中断细胞和病毒受体相互作用来阻断asfv感染的方法
JP2015512395A (ja) 変異糖タンパク質ｃを含む組換えウマヘルペスウイルス‐１ワクチン及びその使用
TWI797603B (zh) 免疫組合物
TW496897B (en) Non-splicing variants of gp350
JP2024500225A (ja) 安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失
EP0605680A1 (fr) Mutants et vaccins du virus de la rhinotracheite infectieuse bovine
de Carlos et al. Isolation and characterization of mutants of vaccinia virus with a modified 94-kDa inclusion protein
CN121752290A (zh) Dev作载体的禽流感h9疫苗
Teninges et al. Rhabdovirus sigma, the hereditary CO2 sensitivity agent of Drosophila: nucleotide sequence of a cDNA clone encoding the glycoprotein
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
CN114480301B (zh) 预防或治疗禽病毒感染症的疫苗
US20250332284A1 (en) Modified plant virus system for delivery of nucleic acids into mammalian cells
WO2025049941A1 (en) Attenuated vaccinia virus vaccines for monkeypox
WO2024258975A1 (en) Lyme disease vaccines and methods of use thereof
KR20250179193A (ko) 아프리카 돼지 열병 바이러스 백신용 다중 에피토프 및 이의 용도
Egyed et al. Genomic and pathogenic studies on a glycoprotein E variant field isolate of bovine herpesvirus 1
KR20200124713A (ko) 외인성 펠라인 파라믹소바이러스 유전자를 발현하는 재조합 바이러스 벡터 시스템 및 이로부터 제조된 백신